PATH-52. Understanding the prevalence of MTAP and CDKN2A/B deletion in gliomas by next generation sequencing
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1004
Abstract: CDKN2A/B (cyclin-dependent kinase inhibitor 2A/B) gene alterations are integral to the diagnosis and prognostication of IDH-mutant gliomas. CDKN2A/B status is commonly assessed by next generation sequencing (NGS) or inferred from loss of the surrogate marker… read more here.
Keywords: deletion; next generation; cdkn2a deletion; mtap deletion ... See more keywords
Abstract 1122: Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-1122
Abstract: Methylthioadenosine phosphorylase (MTAP) deletion in cancer cells induces vulnerability to protein arginine methyltransferase 5 (PRMT5) inhibition, offering a synthetic lethal target. Early-phase clinical trials have shown promising efficacy of PRMT5 inhibitors in MTAP-deleted tumors, but… read more here.
Keywords: mtap deletion; cancer; pan cancer; mtap deleted ... See more keywords